van Bergen P F, Deckers J W, Jonker J J, van Domburg R T, Azar A J, Hofman A
ASPECT Coordinating Centre, Rotterdam, The Netherlands.
Br Heart J. 1995 Aug;74(2):117-21. doi: 10.1136/hrt.74.2.117.
To investigate the efficacy of long term oral anticoagulant treatment in subgroups of patients after myocardial infarction.
Analysis of the effect of anticoagulant treatment in subgroups of hospital survivors of myocardial infarction based upon age, gender, history of hypertension, previous myocardial infarction, smoking habits, diabetes mellitus, Killip class, anterior location of infarction, thrombolytic therapy, and use of beta blockers.
Participants of a multicentre, randomised, double blind, placebo controlled trial that assessed the effect of oral anticoagulant treatment on mortality as well as cerebrovascular and cardiovascular morbidity in 3404 hospital survivors of acute myocardial infarction.
The effect of anticoagulant treatment on recurrent myocardial infarction, cerebrovascular events, and vascular events (the composite endpoint of reinfarction, cerebrovascular event, and vascular death).
Long term anticoagulant treatment was associated with a reduction in mortality of 10% (95% confidence interval -11% to 27%), recurrent myocardial infarction of 53% (41% to 62%), cerebrovascular events of 40% (10% to 60%) and vascular events of 35% (24% to 45%). Treatment effect with respect to recurrent myocardial infarction was comparable among all subgroups of patients. Although treatment effect appeared to be somewhat smaller in females than in males (-11% v -45%), and in patients with diabetes compared to those without (-14% v -42%) with respect to vascular events, none of these differences reached statistical significance. In multivariate analysis, more advanced age, previous myocardial infarction, diabetes mellitus, and heart failure during admission were independently associated with increased incidence of cardiovascular complications.
The relative benefit of long term anticoagulant therapy in survivors of myocardial infarction is not modified by known prognostic factors for cardiovascular disease.
探讨长期口服抗凝治疗对心肌梗死后患者亚组的疗效。
基于年龄、性别、高血压病史、既往心肌梗死、吸烟习惯、糖尿病、Killip分级、梗死部位、溶栓治疗及β受体阻滞剂使用情况,分析抗凝治疗对心肌梗死住院存活患者亚组的影响。
一项多中心、随机、双盲、安慰剂对照试验的参与者,该试验评估了口服抗凝治疗对3404例急性心肌梗死住院存活患者死亡率以及脑血管和心血管发病率的影响。
抗凝治疗对复发性心肌梗死、脑血管事件和血管事件(再梗死、脑血管事件和血管死亡的复合终点)的影响。
长期抗凝治疗与死亡率降低10%(95%置信区间为-11%至27%)、复发性心肌梗死降低53%(41%至62%)、脑血管事件降低40%(10%至60%)以及血管事件降低35%(24%至45%)相关。在所有患者亚组中,抗凝治疗对复发性心肌梗死的治疗效果相当。尽管在血管事件方面,女性的治疗效果似乎比男性小(-11%对-45%),糖尿病患者比非糖尿病患者小(-14%对-42%),但这些差异均未达到统计学意义。多变量分析显示,年龄较大、既往心肌梗死、糖尿病以及入院时心力衰竭与心血管并发症发生率增加独立相关。
已知的心血管疾病预后因素不会改变长期抗凝治疗对心肌梗死存活者的相对益处。